12-month data from the clinical study of OssDsign Catalyst&#

Uppsala, January 24, 2024. OssDsign AB (publ.) today announces that the previously communicated outstanding 12-month results from the clinical study TOP FUSION have been published in the peer-reviewed journal Biomedical Journal of Scientific & Technical Research. The results show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with the novel nanosynthetic bone graft OssDsign Catalyst.

Related Keywords

Stockholm , Sweden , Budapest , Hungary , Morten Henneveld , National Center , Metrics Inc , Company Certified Adviser Is Carnegie Investment Bank , Buda Health Clinic , Biomedical Journal Of Scientific Technical Research , Ossdsign Catalyst , Biomedical Journal , Technical Research , Transforaminal Lumbar Interbody Fusion , Medical Metrics , Oswestry Disability Index , Adverse Events , Dsign Catalyst , Spinal Disorders , Certified Adviser , Carnegie Investment Bank , Nasdaq First North Growth Market ,